Variable | Received nesiritide (n = 2692) | Did not receive nesiritide (n = 22,638) |
---|---|---|
Number (%) | Number (%) | |
Demographic variables* | ||
Race/Ethnicity | ||
Black | 292 (10.9) | 2438 (10.8) |
Hispanic | 266 (9.9) | 1570 (6.9) |
White | 2125 (78.9) | 18,512 (81.8) |
Other race | 9 (0.3) | 118 (0.5) |
Low economic status | 118 (4.4) | 960 (4.2) |
Medications | ||
ACE inhibitors | 1558 (57.9) | 12,173 (53.8) |
Angiotensin II receptor antagonists | 574 (21.3) | 3478 (15.4) |
Diuretics | 2658 (98.7) | 21,650 (95.6) |
Digoxin | 1320 (49.0) | 8925 (39.4) |
Beta blockers | 2114 (78.5) | 13,849 (61.2) |
Dobutamine | 341 (12.7) | 1131 (5.0) |
Dopamine | 315 (11.7) | 1185 (5.2) |
IV nitroglycerin | 313 (11.6) | 1762 (7.8) |
Milrinone | 150 (5.6) | 272 (1.2) |
Severity measures | ||
APR-DRG Severity of Illness | ||
1 or 2 | 1343 (49.9) | 14,653 (64.7) |
3 | 1077 (40.0) | 6979 (30.8) |
4 | 272 (10.1) | 1006 (4.4) |
APR-DRG Risk of Mortality | ||
1 or 2 | 1618 (60.1) | 16,716 (73.8) |
3 | 781 (29.0) | 4661 (20.6) |
4 | 293 (10.9) | 1261 (5.6) |
Outcomes | ||
Hospital mortality | 126 (4.7) | 679 (3.0) |
Prolonged length of stay | 1088 (40.4) | 4973 (22.0) |
Elevated pharmacy cost | 1688 (62.7) | 4640 (20.5) |
Readmission within 31 days for cardiac condition | 340 (12.6) | 2318 (10.2) |